istock-629794242xesai-1
Xesai / iStockphoto.com
19 July 2018Americas

Sanofi in $50m oncology collaboration

Sanofi has partnered with biotechnology company  Revolution Medicines to develop treatments for multiple cancers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019   Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.

More on this story

Big Pharma
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019   Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.

More on this story

Big Pharma
23 August 2018   Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.
Big Pharma
15 January 2019   Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.